Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Am Fam Physician ; 92(4): 261-8, 2015 Aug 15.
Article in English | MEDLINE | ID: mdl-26280231

ABSTRACT

Osteoporosis-related fractures affect approximately one in two white women and one in five white men in their lifetime. The impact of fractures includes loss of function, significant costs, and increased mortality. The U.S. Preventive Services Task Force recommends using dual energy x-ray absorptiometry to screen all women 65 years and older, and younger women who have an increased fracture risk as determined by the World Health Organization's FRAX Fracture Risk Assessment Tool. Although guidelines are lacking for rescreening women who have normal bone mineral density on initial screening, intervals of at least four years appear safe. The U.S. Preventive Services Task Force found insufficient evidence to recommend screening for osteoporosis in men; other organizations recommend screening all men 70 years and older. In patients with newly diagnosed osteoporosis, suggested laboratory tests to identify secondary causes include serum 25-hydroxyvitamin D, calcium, creatinine, and thyroid-stimulating hormone. First-line treatment to prevent fractures consists of fall prevention, smoking cessation, moderation of alcohol intake, and bisphosphonate therapy. Clinicians should consider discontinuing bisphosphonate therapy after five years in women without a personal history of vertebral fractures. Raloxifene, teriparatide, and denosumab are alternative effective treatments for certain subsets of patients and for those who are unable to take or whose condition does not respond to bisphosphonates. The need for follow-up bone mineral density testing in patients receiving treatment for osteoporosis is uncertain.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Diphosphonates/therapeutic use , Osteoporosis/diagnosis , Osteoporosis/drug therapy , Osteoporotic Fractures/prevention & control , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged
3.
Am Fam Physician ; 79(3): 193-200, 2009 Feb 01.
Article in English | MEDLINE | ID: mdl-19202966

ABSTRACT

Osteoporosis affects approximately 8 million women and 2 million men in the United States. The associated fractures are a common and preventable cause of morbidity and mortality in up to 50 percent of older women. The U.S. Preventive Services Task Force recommends using dual energy x-ray absorptiometry to screen all women 65 years and older and women 60 to 64 years of age who have increased fracture risk. Some organizations recommend considering screening in all men 70 years and older. For persons with osteoporosis diagnosed by dual energy x-ray absorptiometry or previous fragility fracture, effective first-line treatment consists of fall prevention, adequate intake of calcium (at least 1,200 mg per day) and vitamin D (at least 700 to 800 IU per day), and treatment with a bisphosphonate. Raloxifene, calcitonin, teriparatide, or hormone therapy maybe considered for certain subsets of patients.


Subject(s)
Absorptiometry, Photon , Aging , Fractures, Bone/prevention & control , Mass Screening , Osteoporosis/diagnosis , Osteoporosis/drug therapy , Absorptiometry, Photon/methods , Aged , Bone Density Conservation Agents/administration & dosage , Calcium/administration & dosage , Drug Therapy, Combination , Estrogen Replacement Therapy/methods , Female , Humans , Male , Mass Screening/methods , Mass Screening/organization & administration , Middle Aged , Osteoporosis/prevention & control , Osteoporosis, Postmenopausal/diagnosis , Osteoporosis, Postmenopausal/drug therapy , Practice Guidelines as Topic , Risk Factors , Treatment Outcome , Vitamin D/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...